WO2015120692A1 - 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 - Google Patents
一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 Download PDFInfo
- Publication number
- WO2015120692A1 WO2015120692A1 PCT/CN2014/082290 CN2014082290W WO2015120692A1 WO 2015120692 A1 WO2015120692 A1 WO 2015120692A1 CN 2014082290 W CN2014082290 W CN 2014082290W WO 2015120692 A1 WO2015120692 A1 WO 2015120692A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyethylene glycol
- glycol monomethyl
- monomethyl ether
- docetaxel
- polylactic acid
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 69
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 69
- 239000000693 micelle Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 238000009472 formulation Methods 0.000 title abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 93
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 92
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 56
- 239000004626 polylactic acid Substances 0.000 claims abstract description 56
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims abstract description 49
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims abstract description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 42
- 229920001400 block copolymer Polymers 0.000 claims abstract description 41
- 239000012876 carrier material Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 239000003960 organic solvent Substances 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 4
- 238000006703 hydration reaction Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000010408 film Substances 0.000 claims 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 39
- 238000005538 encapsulation Methods 0.000 abstract description 11
- 238000000746 purification Methods 0.000 description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- -1 polyethylene monomethyl ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/78—Preparation processes
- C08G63/81—Preparation processes using solvents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/78—Preparation processes
- C08G63/82—Preparation processes characterised by the catalyst used
- C08G63/85—Germanium, tin, lead, arsenic, antimony, bismuth, titanium, zirconium, hafnium, vanadium, niobium, tantalum, or compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
Definitions
- the invention belongs to the technical field of medicine, and in particular relates to a docetaxel nano polymer micelle freeze-dried preparation and a preparation method thereof.
- Docetaxel also known as docetaxel, has a molecular formula of C 43 H 53 N0 14 and a molecular weight of 807.88. It is a paclitaxel antineoplastic agent that binds to free tubulin and promotes tubulin assembly. Stable microtubules, while inhibiting their depolymerization, result in the loss of normal function of microtubule bundles and microtubule fixation, thereby inhibiting cell mitosis and exerting anti-tumor effects. Clinically used for breast cancer, non-small cell lung cancer, pancreatic cancer, soft tissue sarcoma, head and neck cancer, stomach cancer, ovarian cancer and prostate cancer, both drugs alone and in combination have significant effects.
- docetaxel has the disadvantages of poor water solubility, short half-life and high toxicity, which limits its clinical application.
- domestic and foreign marketed docetaxel injection dissolves docetaxel in Tween-80.
- Tween-80 In clinical applications, it is necessary to strictly use a special injection medium to make the dilution operation strict and the use method cumbersome.
- the preparation contains a large amount of Tween, which may cause adverse reactions such as hemolysis and allergy. It is necessary to take dexamethasone and other drugs in advance to prevent and treat the drug. The clinical drug is inconvenient and the drug safety is low. So far, this problem has not been solved well.
- Nano-polymer micelles are drug-loading systems developed in recent years for poorly soluble drugs, having a core-shell structure in which the core is a hydrophobic portion and the shell is a hydrophilic portion.
- Polymer micelles can encapsulate poorly soluble drugs in the core to achieve solubilization of poorly soluble drugs.
- the polymer micelle drug-loading system is highly safe because it selects biodegradable materials as materials. Therefore, as an encapsulating auxiliary material for poorly soluble drugs, it has a good application prospect.
- Polyethylene glycol monomethyl ether-polylactic acid block polymer and docetaxel-prepared micelles have been tried in many techniques to solve this problem.
- CN201110105540 discloses a polyethylene glycol monomethyl ether- Polylactic acid block polymer and docetaxel prepared micelles solve the problem of solubilization of docetaxel.
- CN201010114289 discloses a technique for improving the stability of micelles after reconstitution by adding amino acids to polymer micelles, but the added substances are more demanding for industrial production, and the added stabilizers are increased.
- the cumbersomeness of the preparation process, and the addition of amino acids and the like have a degrading effect on the main drug, and are not suitable for the production of large production. Summary of the invention
- the present invention provides a docetaxel nano polymer micelle lyophilized preparation, wherein the docetaxel nano polymer micelle has a higher encapsulation efficiency after being dispersed with water. 90% of the time can reach more than 12 hours.
- Another technical problem to be solved by the present invention is to provide a method for preparing the above docetaxel nanopolymer micelle lyophilized preparation and an application thereof.
- a docetaxel nanopolymer micelle lyophilized preparation comprising polyethylene glycol monomethyl ether-polylactic acid block copolymer carrier material and docetaxel, docetaxel wrapped in a carrier
- the mass ratio of docetaxel to the carrier material is 0.01 to 0.15
- the polyethylene glycol monomethyl ether-polylactic acid block copolymer is D, L-lactide and polyethylene glycol single
- the block copolymer formed by ring-opening polymerization of methyl ether has a mass ratio of polyethylene glycol monomethyl ether to D, L-lactide of 1:0.55-0.65 or 1:0.73-0.89 or 1:0.91-0.99.
- the mass ratio of the polyethylene glycol monomethyl ether to the D, L-lactide has a great influence on the encapsulation efficiency of the synthesized block copolymer after water reconstitution after forming a micelle, so the polycondensation is strictly controlled.
- the amount of ethylene glycol monomethyl ether and D, L-lactide is strictly controlled.
- the mass ratio of the docetaxel to the carrier material is from 0.02 to 0.09.
- the polyethylene glycol monomethyl ether has a molecular weight of from 1,000 to 20,000. Preferably, the polyethylene glycol monomethyl ether has a molecular weight of 2,000 or 5,000.
- the invention also provides a preparation method of the above docetaxel nano polymer micelle lyophilized preparation, comprising the following steps:
- the micelle solution prepared in the step (2) is sterilized by filtration and freeze-dried to obtain a docetaxel nano polymer micelle lyophilized preparation.
- the polyethylene glycol monomethyl ether-polylactic acid block copolymer carrier material is prepared by the following method: weigh the formula amount of D, L-lactide and polyethylene glycol monomethyl ether for use, The formulated amount of polyethylene glycol monomethyl ether was vacuum dried in the reactor at 60-130 ° C for 2-8 h, replaced with nitrogen, then the formula amount of D, L-lactide was added, and then the catalyst stannous octoate was added.
- the quality of stannous octoate accounts for 0.05% ⁇ 0.5wt% of the total mass of D, L-lactide and polyethylene glycol monomethyl ether, and then vacuum is applied to maintain the reaction temperature at 60 ⁇ 130 °C, to D, L After all the lactide has been melted, replace it with nitrogen three times, then vacuum again to ensure that the reactor is under negative pressure, sealed or protected by nitrogen, then warmed to 125 ⁇ 150 °C, the reaction is 6 ⁇ 20 h, the reaction is completed, and the reaction is light.
- the organic solvent is any one or more of acetonitrile, methanol, acetone, dichloromethane, dimethylformamide, dimethyl hydrazine, tetrahydrofuran, acetone, short-chain fatty alcohol and ethyl acetate.
- the organic solvent is used in an amount of 0.2 to 1 ml of an organic solvent per gram of the pale yellow clear viscous liquid.
- the organic solvent is any one of acetonitrile, methanol, acetone or ethyl acetate.
- anhydrous glacial ether is used in an amount of 5-10 ml of anhydrous glacial ether per gram of pale yellow clear viscous liquid.
- water is added to the drug film in an amount of from 2 to 40 ml of water per gram of the polyethylene glycol monomethyl ether polylactic acid block copolymer carrier material, more preferably per gram of polyethylene glycol monomethyl ether.
- the polylactic acid block copolymer carrier material is added with 5 to 25 ml of water.
- the conditions for removing the organic solvent by rotary evaporation are: rotation speed 10 to 150 rpm, temperature 20 to 80 ° C, time l ⁇ 4ho
- the block copolymer prepared by using a suitable mass ratio of polyethylene glycol monomethyl ether and D, L-lactide is used as a carrier material, and at the same time, a ratio of a suitable drug to a carrier material is selected, so that
- the prepared docetaxel nano-polymer micelle lyophilized preparation can have an encapsulation efficiency of more than 90% after water dispersing for more than 12 hours, and the effect is far superior to the ordinary lyophilized preparation, which is in line with the actual situation of clinical drug application. To meet clinical requirements.
- docetaxel is better encapsulated by the carrier, thereby improving stability.
- Figure 1 is a CDCl ⁇ H NMR spectrum of a polyethylene glycol monomethyl ether polylactic acid block copolymer
- Figure 2 is a GPC spectrum of polyethylene glycol monomethyl ether polylactic acid block copolymer
- Figure 3 is a CDC1 3 1H NMR spectrum of the docetaxel polymer micelle lyophilized preparation
- Figure 4 is a D 2 0 1H NMR spectrum of the docetaxel polymer micelle lyophilized preparation
- Figure 5 is a CDC1 3 1H NMR spectrum of a polyethylene glycol monomethyl ether polylactic acid block copolymer
- Figure 6 is an infrared spectrum of polyethylene glycol monomethyl ether polylactic acid block copolymer
- Figure 7 is the infrared spectrum of docetaxel
- Figure 8 is an infrared spectrum of docetaxel polymer micelles
- Figure 9 is a thermal scan of docetaxel
- Figure 10 is a thermal scanning spectrum of a polyethylene glycol monomethyl ether polylactic acid block copolymer
- Figure 11 is a thermal scanning chromatogram of docetaxel polymer micelles.
- Figure 1 is a graph showing the characterization of various hydrogens in a polyethylene glycol monomethyl ether-polylactic acid block copolymer, demonstrating the synthesis of a polyethylene glycol monomethyl ether-polylactic acid block copolymer.
- the test results of Fig. 2 are as follows: Mp: 6330; Mn : 5887; Mw: 6374; Mz: 6873; Mz +1 : 7393; Mv: 6301; PDI: 1.08272.
- Example 2 Preparation of Polyethylene Glycol Monomethyl Ether-Polylactic Acid Block Polymer.
- a docetaxel nano polymer micelle lyophilized preparation was prepared according to the amount in Table 1, wherein the rotation speed was controlled between 10 and 150 rpm, and the temperature was between 20 and 80 °C. , time l ⁇ 4h.
- Example 32 400 6 400 4000
- Example 33 1 0.65 400 36 Methanol 600 5000
- Example 34 400 60 800 6000
- Example 35 400 8 400 4000 Short chain
- Example 36 1:0.60 400 40 600 5000 Fatty alcohol
- Example 37 400 55 800 6000
- Example 38 400 4 400 4000 Short chain
- Example 39 1:0.55 400 36 600 5000 Fatty alcohol
- FIG. 3 is a CDC1 3 1H NMR spectrum of the docetaxel nanopolymer micelle lyophilized preparation prepared in Example 11
- Figure 4 is a D of the docetaxel polymer micelle lyophilized preparation prepared in Example 11.
- FIG. 5 is a CDC1 3 1H NMR spectrum of the polyethylene glycol monomethyl ether polylactic acid block copolymer prepared in Example 1. The results showed that docetaxel was encapsulated in the core of the micelle, and the characteristic absorption peak of docetaxel in the ⁇ NMR spectrum of the micelle was not observed.
- Example 11 A small amount of the docetaxel nanopolymer micelle lyophilized preparation prepared in Example 11, the docetaxel and the polyethylene glycol monomethyl ether polylactic acid prepared in Example 1 were subjected to Fourier transform infrared spectroscopy. Scanning, the results are shown in Figures 6, 7, and 8, demonstrating that docetaxel is encapsulated in the core of the micelle without the characteristic absorption peak of docetaxel in the infrared spectrum of the micelle.
- Example 12 A small amount of the docetaxel nanopolymer micelle lyophilized preparation prepared in Example 11, the docetaxel, and the polyethylene glycol monomethyl ether polylactic acid prepared in Example 1 were subjected to thermal analysis scanning, and the results were as follows. As shown in Fig. 9, Fig. 10 and Fig. 11, it was proved that docetaxel was encapsulated in the core of the micelle, and the characteristic absorption peak of docetaxel in the thermal scanning spectrum of the micelle was not observed.
- Example 42 Detection results of encapsulation efficiency at different times after reconstitution of docetaxel nanopolymer micelle lyophilized preparation.
- a reference drug was prepared in accordance with the prescription 17 (mass ratio of polyethylene glycol to polylactic acid of 1:1.2, drug loading of 6%) in Example 1 disclosed in CN201110105540.2.
- a docetaxel nanopolymer micelle lyophilized preparation was prepared according to Example 11 of the present invention.
- the experimental group was subjected to three parallel experiments, which were labeled as Example 11-1, Example 11-2, and Example 11- 3.
- the preparations of the control group and the experimental group were dissolved in physiological saline to a concentration of 1 mg/ml (based on docetaxel) and the encapsulation efficiency was measured at room temperature (25 ⁇ 2 ° C) at different times. The results are shown in Table 2.
- the encapsulation efficiency of the micelles by high-speed centrifugation (10000 r/min, lOmin), wherein the encapsulation ratio (1-free drug/total drug) X 100%.
- the chromatographic conditions for the determination of the encapsulation efficiency of docetaxel polymer micelles were as follows: ODS was used as a filler, and O.043 mol/L ammonium acetate aqueous solution-acetonitrile (45:55) was used as a mobile phase, and the detection wavelength was 230 nm. The number of theoretical plates should be no less than 2000 according to the Docetaxel peak.
- the encapsulation efficiency of the experimental group was still greater than 90% at 12h, while the control group had a burst at 0.5h.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Polyethers (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/897,488 US10066052B2 (en) | 2014-02-14 | 2014-07-16 | Docetaxel nano-polymer micelle lyophilized preparation and preparation method thereof |
JP2016522249A JP6147427B2 (ja) | 2014-02-14 | 2014-07-16 | ドセタキセルのナノポリマーミセルの凍結乾燥製剤の調製方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410050783 | 2014-02-14 | ||
CN201410050783.4 | 2014-02-14 | ||
CN201410326208.2 | 2014-07-10 | ||
CN201410326208.2A CN104758256B (zh) | 2014-02-14 | 2014-07-10 | 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015120692A1 true WO2015120692A1 (zh) | 2015-08-20 |
Family
ID=53640592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/082290 WO2015120692A1 (zh) | 2014-02-14 | 2014-07-16 | 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 |
PCT/CN2014/082293 WO2015120693A1 (zh) | 2014-02-14 | 2014-07-16 | 一种聚乙二醇单甲醚-聚乳酸嵌段共聚物及其制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/082293 WO2015120693A1 (zh) | 2014-02-14 | 2014-07-16 | 一种聚乙二醇单甲醚-聚乳酸嵌段共聚物及其制备方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US9683073B2 (zh) |
JP (2) | JP6250802B2 (zh) |
CN (2) | CN104758256B (zh) |
WO (2) | WO2015120692A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101748191B1 (ko) * | 2015-07-28 | 2017-06-19 | 주식회사 삼양바이오팜 | 보관 안정성이 향상된 약학 조성물 및 그의 제조 방법 |
US20170028068A1 (en) | 2015-07-29 | 2017-02-02 | Samyang Biopharmaceuticals Corporation | Pharmaceutical composition with improved storage stability and method for preparing the same |
CN105343000A (zh) * | 2015-10-16 | 2016-02-24 | 姚俊华 | 一种多西他赛胶束聚合物的制备方法和应用 |
CN106995528B (zh) * | 2016-01-26 | 2020-01-10 | 浙江大学 | 一种聚乙二醇单甲醚-聚乳酸嵌段共聚物的精制方法 |
CN106361697B (zh) * | 2016-08-26 | 2019-06-07 | 四川兴康脉通医疗器械有限公司 | 一种含有布洛芬的载紫杉醇胶束聚合物、制剂及制备方法 |
WO2018047074A1 (en) | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
CN106589337B (zh) * | 2016-12-12 | 2019-07-02 | 上海交通大学医学院附属第九人民医院 | 可降解生物薄膜、其制备方法以及硝唑类缓释制剂 |
CN108309936B (zh) * | 2018-04-02 | 2020-04-28 | 新疆农业大学 | 载番茄红素自组装纳米胶束及其制备方法 |
CN108498854B (zh) * | 2018-04-27 | 2021-06-15 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 一种负载纳米缓释药物胶束和载银微球的膨胀海绵及其制备方法及用途 |
CN109172520A (zh) * | 2018-09-11 | 2019-01-11 | 沈阳东星医药科技有限公司 | 一种紫杉烷类衍生物tm-2胶束注射液及其制备方法与应用 |
CN110917149A (zh) * | 2018-12-26 | 2020-03-27 | 银谷制药有限责任公司 | 一种包载难溶性抗肿瘤药物的聚合物胶束冻干制剂 |
CN110358063B (zh) * | 2019-04-19 | 2021-10-19 | 深圳普洛美康材料有限公司 | 嵌段共聚物mPEG-b-PLA的制备方法 |
CN110585140A (zh) * | 2019-07-08 | 2019-12-20 | 苏州海特比奥生物技术有限公司 | 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法 |
CN110922816B (zh) * | 2019-12-06 | 2021-07-23 | 山东方大杭萧钢构科技有限公司 | 一种低voc含量的水性膨胀钢结构防火涂料及其制备方法 |
CN111888523A (zh) * | 2020-09-08 | 2020-11-06 | 尹振宇 | 一种用于改善肌肤的聚乳酸凝胶的制备方法 |
CN114712312B (zh) * | 2020-12-18 | 2023-10-24 | 浙江圣兆药物科技股份有限公司 | 一种控制微球活性成分释放的方法 |
CN113197852B (zh) * | 2021-04-20 | 2022-12-09 | 上海应用技术大学 | 大麻二酚纳米胶束制剂及其制备方法 |
CN113476402B (zh) * | 2021-07-05 | 2023-08-01 | 苏州大学 | 一种多西他赛胶束纳米药物及其制备方法与应用 |
CN117999304A (zh) * | 2021-09-03 | 2024-05-07 | 南京再明医药有限公司 | 一种疏水性药物聚合物胶束及其制备方法 |
WO2023082634A1 (zh) * | 2021-11-10 | 2023-05-19 | 渼颜空间(河北)生物科技有限公司 | 一种可生物降解的共聚物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804021A (zh) * | 2010-04-21 | 2010-08-18 | 山东大学 | 载多烯紫杉醇纳米粒混合胶束制剂及冻干剂的制备方法 |
CN101972480A (zh) * | 2010-01-19 | 2011-02-16 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的多西他赛聚合物胶束药物组合物 |
CN102219892A (zh) * | 2010-06-30 | 2011-10-19 | 上海谊众生物技术有限公司 | 聚乙二醇单甲醚-dl-聚乳酸嵌段共聚物的制备方法 |
CN102885772A (zh) * | 2012-09-29 | 2013-01-23 | 山东大学 | 一种载多烯紫杉醇混合胶束制剂及其制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010022708A (ko) * | 1997-08-08 | 2001-03-26 | 프레드한 아룬디프 에스 | 약물 수송에 이용할 수 있는 생분해가능한 주사용 블록공중합체 겔 |
KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
CN1206002C (zh) * | 2002-12-02 | 2005-06-15 | 天津大学 | 组合聚合物药物胶束及其制备方法 |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
TW200624464A (en) * | 2004-12-31 | 2006-07-16 | Ind Tech Res Inst | Amphiphilic block copolymer and pharmaceutical formulation comprising the same |
CN100352508C (zh) * | 2005-01-17 | 2007-12-05 | 涂家生 | 一种眼用嵌段聚合物 |
KR101024742B1 (ko) * | 2007-12-31 | 2011-03-24 | 주식회사 삼양사 | 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법 |
JP2010059354A (ja) * | 2008-09-05 | 2010-03-18 | Kyoto Institute Of Technology | ポリ乳酸組成物 |
JP5449388B2 (ja) * | 2008-11-21 | 2014-03-19 | サミャン バイオファーマシューティカルズ コーポレイション | 耐性がん治療用高分子ミセル組成物及びその製造方法 |
CN101422615B (zh) * | 2008-12-09 | 2013-01-23 | 沈阳药科大学 | 一种冬凌草甲素聚合物胶束给药制剂及制备方法 |
EP2201935B1 (en) * | 2008-12-26 | 2020-07-08 | Samyang Biopharmaceuticals Corporation | Polymeric micelle composition containing a poorly soluble drug and preparation method of the same |
CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
US8883955B2 (en) * | 2009-06-19 | 2014-11-11 | Toyo Engineering Corporation | Method for producing polylactic acid |
EP2460539A4 (en) * | 2009-07-31 | 2013-12-04 | Xi An Libang Medical Technology Co Ltd | MEDICAMENT IN THE FORM OF NANO OR MICROBALLS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION THEREOF AND USE THEREOF |
CN101732234A (zh) * | 2010-01-19 | 2010-06-16 | 山东大学 | 载有多西他赛的嵌段聚合物胶束冻干制剂的制备方法 |
CN102181048B (zh) * | 2011-03-11 | 2015-02-25 | 上海谊众生物技术有限公司 | 一种生物医用聚醚/聚酯嵌段共聚物的制备方法 |
CN102218027B (zh) * | 2011-04-22 | 2014-07-02 | 上海谊众生物技术有限公司 | 一种包载难溶性抗肿瘤药物的聚合物胶束冻干制剂 |
CN102266294B (zh) * | 2011-07-25 | 2012-12-05 | 浙江大学 | 一种包载亲水性药物的微球制剂及其制备方法 |
CN102274163B (zh) * | 2011-08-12 | 2013-01-02 | 山东大学 | 一种姜黄素纳米胶束制剂及其制备方法 |
CN103772686B (zh) * | 2012-10-26 | 2015-01-07 | 苏州雷纳药物研发有限公司 | 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统 |
-
2014
- 2014-07-10 CN CN201410326208.2A patent/CN104758256B/zh active Active
- 2014-07-10 CN CN201410326099.4A patent/CN104761710B/zh active Active
- 2014-07-16 JP JP2016522250A patent/JP6250802B2/ja active Active
- 2014-07-16 WO PCT/CN2014/082290 patent/WO2015120692A1/zh active Application Filing
- 2014-07-16 JP JP2016522249A patent/JP6147427B2/ja active Active
- 2014-07-16 US US14/897,504 patent/US9683073B2/en active Active
- 2014-07-16 WO PCT/CN2014/082293 patent/WO2015120693A1/zh active Application Filing
- 2014-07-16 US US14/897,488 patent/US10066052B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972480A (zh) * | 2010-01-19 | 2011-02-16 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的多西他赛聚合物胶束药物组合物 |
CN101804021A (zh) * | 2010-04-21 | 2010-08-18 | 山东大学 | 载多烯紫杉醇纳米粒混合胶束制剂及冻干剂的制备方法 |
CN102219892A (zh) * | 2010-06-30 | 2011-10-19 | 上海谊众生物技术有限公司 | 聚乙二醇单甲醚-dl-聚乳酸嵌段共聚物的制备方法 |
CN102885772A (zh) * | 2012-09-29 | 2013-01-23 | 山东大学 | 一种载多烯紫杉醇混合胶束制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160137775A1 (en) | 2016-05-19 |
WO2015120693A1 (zh) | 2015-08-20 |
JP2016528187A (ja) | 2016-09-15 |
CN104761710B (zh) | 2016-06-29 |
CN104758256A (zh) | 2015-07-08 |
JP2016523302A (ja) | 2016-08-08 |
JP6250802B2 (ja) | 2017-12-20 |
US9683073B2 (en) | 2017-06-20 |
US10066052B2 (en) | 2018-09-04 |
CN104758256B (zh) | 2016-05-04 |
US20160128940A1 (en) | 2016-05-12 |
JP6147427B2 (ja) | 2017-06-14 |
CN104761710A (zh) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015120692A1 (zh) | 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 | |
Danafar | Study of the composition of polycaprolactone/poly (ethylene glycol)/polycaprolactone copolymer and drug-to-polymer ratio on drug loading efficiency of curcumin to nanoparticles | |
Khan et al. | Process optimization of ecological probe sonication technique for production of rifampicin loaded niosomes | |
Wan et al. | Structure‐guided engineering of cytotoxic cabazitaxel for an adaptive nanoparticle formulation: Enhancing the drug safety and therapeutic efficacy | |
CN110218312B (zh) | 具有高效药物负载性能的聚合物的制备方法 | |
CN103768013A (zh) | 以精制两亲性嵌段共聚物为载体的紫杉醇聚合物胶束 | |
Yang et al. | l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel | |
CN106317416B (zh) | 一种双pH响应的两亲性共聚物及其制备方法和用途 | |
Hu et al. | Core cross-linked polyphosphoester micelles with folate-targeted and acid-cleavable features for pH-triggered drug delivery | |
CN105232459B (zh) | 一种复溶自组装的水难溶性药物聚合物胶束组合物及其制备方法 | |
WO2009084801A1 (en) | Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same | |
Jiang et al. | Facile Fabrication of Thermo‐Responsive and Reduction‐Sensitive Polymeric Micelles for Anticancer Drug Delivery | |
Gu et al. | Reverse micelles based on biocompatible β-cyclodextrin conjugated polyethylene glycol block polylactide for protein delivery | |
Ma et al. | Iminoboronate-based dual-responsive micelles via subcomponent self-assembly for hydrophilic 1, 2-diol-containing drug delivery | |
Jin et al. | Rational design of shear-thinning supramolecular hydrogels with porphyrin for controlled chemotherapeutics release and photodynamic therapy | |
Hu et al. | Paclitaxel prodrug nanoparticles combining chemical conjugation and physical entrapment for enhanced antitumor efficacy | |
Ye et al. | Development of a pluronic-zein-curcumin drug delivery system with effective improvement of hydrophilicity, stability and sustained-release | |
CN103159959A (zh) | 一种m-plga-tpgs星型两亲性共聚物及其制备方法与应用 | |
CN106995528B (zh) | 一种聚乙二醇单甲醚-聚乳酸嵌段共聚物的精制方法 | |
Zhang et al. | Preparation of core cross-linked PCL-PEG-PCL micelles for doxorubicin delivery in vitro | |
Cunningham et al. | Polymers made of bile acids: From soft to hard biomaterials | |
Liu et al. | pH responsive self-assembly and drug release behavior of aliphatic liquid crystal block polycarbonate with pendant cholesteryl groups | |
CN110585140A (zh) | 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法 | |
Chen et al. | Indometacin-loaded micelles based on star-shaped PLLA-TPGS copolymers: effect of arm numbers on drug delivery | |
He et al. | Photo-cross-linked poly (ether amine) micelles for controlled drug release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14882723 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14897488 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016522249 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14882723 Country of ref document: EP Kind code of ref document: A1 |